Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New state-of-the-art research facilities in Oxford will help enhance the treatment of musculoskeletal injuries, strengthen the fight against bone cancer and improve arthritis care.

Research teams have moved into the £6m “phase 2” of the Botnar Research Centre, based on the Nuffield Orthopaedic Centre site.

It makes the Oxford University research facility one of the largest musculoskeletal research centres in Europe, doubling its size to ensure it continues to compete with leading institutions on the world stage.

Phase 2 is the culmination of a seven year fundraising campaign by the NOC Appeal, the same independent charity that previously raised more than £5m to build the original Botnar Research Centre.

NOC Appeal director Jeanette Franklin, who was made an MBE for her work fundraising work, said: “This is a dream. It started back in the early 1990s when we set a target of raising £1m towards building the first phase of the Botnar. That became £5m and the centre opened its doors in 2002. Our vision always included a second phase and it is wonderful to see research teams moving in.”

The Botnar Research Centre now comprises 4,000sqm of custom built research facilities including state-of-the-art laboratories, flexible office accommodation and dedicated “write up” areas.

It can house up to 250 scientists, clinicians and support staff carrying out pioneering research in to conditions such as osteoporosis, osteoarthritis and cancer.  Research will include genetics and cell biology, orthopaedic engineering and surgery, clinical research and epidemiological studies.

It will also house research carried out by the National Institute for Health Research Oxford Biomedical Research Unit (Oxford BRU), a collaboration between Oxford University NHS Hospitals Trust and Oxford University to accelerate innovation in musculoskeletal research.

The opening of phase 2 of the Botnar Research Centre also marks the start of an exciting year for musculoskeletal research and treatment in Oxford.

This autumn, the Kennedy Institute of Rheumatology will open its new building at the University’s neighbouring Old Road campus. The institute, founded in 1965, transferred to Oxford University in 2011.

The Kennedy Institute, the Botnar Research Centre, and the Nuffield Orthopaedic Centre, will bring together world class basic research, translational research and NHS treatment at one location.

Professor Andy Carr, Divisional Director at the NOC and Director of the Botnar Research Centre and the NIHR Oxford BRU said: “Since it opened in 2002, the Botnar Research Centre has established itself as a world leading centre for musculoskeletal research. This annexe will strengthen our efforts and provide our researchers and clinicians with the best possible facilities”.

“We would like to say thank you to all those who contributed to the magnificent fundraising campaign that has made this world-class facility a reality.  Their hard work will help us improve the quality of life for those people who suffer from debilitating musculoskeletal conditions such as arthritis and osteoporosis.”

Links:

Botnar Research Centre


Watch: BBC News

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.

Oxford-led technology to help those at high risk from Covid-19

Coronavirus COVID-19 General Research

More people in England at high risk from Covid-19 will get priority access to vaccines thanks to new technology developed by a University of Oxford-led team of researchers that can identify those who may be most vulnerable to the virus.